The JAK/STAT pathway in rheumatoid arthritis: Pathogenic or protective?

Arthritis and Rheumatism

Volumn 48, Issue 8, 2003, Pages 2092-2096

  Ivashkiv, Lionel B ^a,b   Hu, Xiaoyu ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; JANUS KINASE; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN;

ARTHRITIS; CYTOKINE PRODUCTION; EDITORIAL; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVITIS;

ARTHRITIS, RHEUMATOID; DNA-BINDING PROTEINS; HUMANS; JANUS KINASE 1; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 0043074740     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11095     Document Type: Editorial

References (42)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
2. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? II. T cell-independent mechanisms from beginning to end. Arthritis Rheum 2002;46:298-308.
3. Firestein GS, Manning AM. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999;42:609-21.
4. Muller-Ladner U, Gay RE, Gay S. Role of nuclear factor kappaB in synovial inflammation. Curr Rheumatol Rep 2002;4:201-7.
5. Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S, et al. Is NF-kappaB a useful therapeutic target in rheumatoid arthritis? Ann Rheum Dis 2002;61 Suppl 2:ii13-8.
6. Schett G, Tohidast-Akrad M, Steiner G, Smolen J. The stressed synovium. Arthritis Res 2001;3:80-6.
7. Pope RM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2002;2:527-35.
8. Ivashkiv LB. Cytokine expression and cell activation in inflammatory arthritis. Adv Immunol 1996;63:337-76.
9. Choy EHS, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46:3143-50.
10. Van der Pouw Kraan TCTM, van Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC, et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 2003;48:2132-45.
11. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322.
12. Sengupta TK, Chen A, Zhong Z, Darnell JE Jr, Ivashkiv LB. Activation of monocyte effector genes and STAT family transcription factors by inflammatory synovial fluid is independent of interferon gamma. J Exp Med 1995;181:1015-25.
13. Wang F, Sengupta TK, Zhong Z, Ivashkiv LB. Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids. J Exp Med 1995;182:1825-31.
14. Yokota A, Narazaki M, Shima Y, Murata N, Tanaka T, Suemura M, et al. Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial fluid cells. J Rheumatol 2001;28:1952-9.
15. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001;108:1781-8.
16. Frucht DM, Aringer M, Galon J, Danning C, Brown M, Fan S, et al. Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol 2000;164:4659-64.
17. Muller-Ladner U, Judex M, Ballhorn W, Kullmann F, Distler O, Schlottmann K, et al. Activation of the IL-4 STAT pathway in rheumatoid synovium. J Immunol 2000;164:3894-901.
18. Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE, et al. Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation. Nat Immunol 2002;3:859-66.
19. Zanders ED, Goulden MG, Kennedy TC, Kempsell KE. Analysis of immune system gene expression in small rheumatoid arthritis biopsies using a combination of subtractive hybridization and high-density cDNA arrays. J Immunol Methods 2000;233:131-40.
20. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol 2000;18:143-64.
21. Ivashkiv LB. Cytokines and STATs: how can signals achieve specificity? Immunity 1995;3:1-4.
22. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996;15:3651-8.
23. Firestein GS, Zvaifler NJ. Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that γ-interferon is not the primary macrophage activating factor. Arthritis Rheum 1987;30:864-71.
24. Egan PJ, Lawlor KE, Alexander WS, Wicks IP. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J Clin Invest 2003;111:915-24.
25. Ivashkiv LB, Tassiulas I. Can SOCS make arthritis better? J Clin Invest 2003;111:795-7.
26. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996;84:443-50.
27. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996;84:431-42.
28. Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR, et al. Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci U S A 2001;98:6680-5.
29. Ramana CV, Gil MP, Han Y, Ransohoff RM, Schreiber RD, Stark GR. Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A 2001;98:6674-9.
30. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 1997;17:5328-37.
31. Lee CK, Smith E, Gimeno R, Gertner R, Levy DE. STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-gamma. J Immunol 2000;164:1286-92.
32. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468-73.
33. Krause A, Scaletta N, Ji JD, Ivashkiv LB. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol 2002;169:6610-6.
34. De Hooge ASK, van de Loo FAJ, Kolbe T, Mueller M, Levy DE, Bennink M, et al. STAT1 and STAT3 activation during the course of experimental arthritis [abstract]. Arthritis Rheum 2002;46 Suppl 9:S250.
35. Boissier MC, Chiocchia G, Bessis N, Hajnal J, Garotta G, Nicoletti F, et al. Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur J Immunol 1995;25:1184-90.
36. Atsumi T, Ishihara K, Kamimura D, Ikushima H, Ohtani T, Hirota S, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 2002;196:979-90.
37. Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 2000;19:2607-11.
38. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999;10:39-49.
39. Stepkowski SM, Erwin-Cohen RA, Behbod F, Wang ME, Qu X, Tejpal N, et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002;99:80-9.
40. Uckun FM, Roers BA, Waurzyniak B, Liu XP, Cetkovic-Cvrlje M. Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood 2002;99:4192-9.
41. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
42. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002;1:117-23.